Drug intelligence / Profile preview

HMBD-804

Development stage: Preclinical
Lead developer: Callio Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

HMBD-804 is a preclinical-stage antibody-drug conjugate (ADC) originally developed by Hummingbird Bioscience and now licensed to Callio Therapeutics. It is described as a dual-payload ADC, meaning it carries two cytotoxic payloads designed to enhance anti-tumor efficacy and potentially overcome resistance mechanisms seen with single-payload ADCs. The specific molecular target of HMBD-804 has not been publicly disclosed as of June 2025. The drug remains in the preclinical phase, with its primary development focus in oncology[1][2][3].

Beyond the preview

Go deeper on HMBD-804.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMBD-804.

Explore the full profile